West Pharmaceutical Services (NYSE:WST) Issues Earnings Results

West Pharmaceutical Services (NYSE:WST) released its quarterly earnings data on Thursday. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29, Zacks reports. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The company had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same period in the previous year, the business earned $1.84 earnings per share. The company’s quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services updated its Q3 2026 guidance to 2.140-2.240 EPS and its FY 2026 guidance to 8.850-9.050 EPS.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

• West delivered Q2 2026 results above expectations, with revenue of $872 million up 13% organically and adjusted EPS of $2.37 up 29% year over year.
• The company raised full-year guidance to 10%-11% organic revenue growth and adjusted EPS of $8.85-$9.05, citing strong momentum in the business.
• High-value product components were the main growth engine, with organic growth of 18% led by biologics, Annex 1-related upgrades, and GLP-1 demand. Management said non-GLP-1 HVP components outperformed expectations and still have a multi-year runway.
• The cyber incident still affected West Vantage, holding Q2 growth to 1% and shifting some revenue into the second half. Management said the impact should be made up later this year, with Q3 expected to be the trough for the segment.
• Gross margin and operating margin both improved meaningfully in the quarter, helped by stronger sales mix, pricing, and leverage from higher revenue. West also continued share repurchases, buying back $157 million of stock in Q2.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST traded up $1.87 during midday trading on Thursday, hitting $360.28. 742,744 shares of the company’s stock were exchanged, compared to its average volume of 897,857. The firm has a market capitalization of $25.45 billion, a PE ratio of 48.44, a price-to-earnings-growth ratio of 2.91 and a beta of 1.16. The company’s 50 day moving average price is $335.41 and its 200 day moving average price is $286.58. West Pharmaceutical Services has a 12 month low of $223.83 and a 12 month high of $386.00. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is 11.76%.

Insider Activity

In related news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Chad Winters sold 896 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. This represents a 37.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.60% of the company’s stock.

Institutional Trading of West Pharmaceutical Services

A number of institutional investors and hedge funds have recently added to or reduced their stakes in WST. CYBER HORNET ETFs LLC bought a new stake in West Pharmaceutical Services in the second quarter valued at $25,000. DV Equities LLC bought a new position in West Pharmaceutical Services during the fourth quarter valued at about $28,000. MUFG Securities EMEA plc purchased a new position in West Pharmaceutical Services in the second quarter valued at approximately $47,000. State of Wyoming bought a new position in West Pharmaceutical Services during the second quarter valued at $49,000. Finally, Meeder Asset Management Inc. increased its position in West Pharmaceutical Services by 1,023.5% in the fourth quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 174 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on WST shares. KeyCorp boosted their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Citigroup restated a “buy” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Wolfe Research assumed coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price on the stock. Finally, Evercore reaffirmed an “outperform” rating and set a $410.00 price target on shares of West Pharmaceutical Services in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has a consensus rating of “Buy” and a consensus price target of $363.17.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West raised full-year 2026 EPS guidance to $8.85-$9.05, above consensus, and lifted revenue guidance to $3.3 billion-$3.4 billion, also at or above Wall Street expectations. Reuters: West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
• Positive Sentiment: The company also issued stronger third-quarter guidance, with EPS of $2.14-$2.24 and revenue of $820 million-$835 million, both slightly ahead of analyst estimates. PR Newswire: West Reports Second-Quarter 2026 Results
• Neutral Sentiment: West declared a quarterly dividend of $0.22 per share, reinforcing its shareholder-return policy, though the yield remains modest. PR Newswire: West Declares Quarterly Dividend
• Negative Sentiment: Earlier commentary suggested the stock was looking expensive with limited upside near fair value, which could temper enthusiasm after the post-earnings move. Yahoo Finance: West (WST) Stock Looks Pricey With Little Room Above Fair Value

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.